The DOI matches its Crossref record.
A Placebo-Controlled Comparison of the Efficiency of Triple- and Monotherapy in Category III B Chronic Pelvic Pain Syndrome (CPPS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most (eight) showed positive results, with significant differences vs placebo in NIH‐CPSI total, urinary symptom, pain, and/or QoL scores 54, 55, 56, 57, 59, 60, or in scores using other validated symptom scoring tools 58, 61.”
From Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline (2015) · cites this paper as [59]
In the citing paper
“In all, 10 placebo‐controlled RCTs (n = 58–272) were identified that evaluated α‐adrenergic antagonists (tamsulosin 53, 54, 55, alfuzosin 56, 57, doxazosin 58, 59, terazosin 60, 61 and silodosin 62) in CBP and CP/CPPS.”
From Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline (2015) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 23
- McNaughton-Collins, 1998, How common is prostatitis? A national survey of physician visits, J Urol, 159, 1224, 10.1016/S0022-5347(01)63564-X · DOI · Paper page
- Wenninger, 1996, Sickness impact of chronic nonbacterial prostatitis and its correlates, J Urol, 155, 965, 10.1016/S0022-5347(01)66359-6 · DOI · Paper page
- Calhoun, 2004, The economic impact of chronic prostatitis, Arch Intern Med, 164, 1231, 10.1001/archinte.164.11.1231 · DOI
- Krieger, 1999, NIH consensus definition and classification of prostatitis, JAMA, 282, 236, 10.1001/jama.282.3.236 · DOI · Paper page
- Nickel, 1999, Prostatitis: Evolving management strategies, Urol Clin North Am, 26, 737, 10.1016/S0094-0143(05)70215-9 · doi:10.1016/s0094-0143(05)70215-9
- Meares, 1968, Bacteriologic localization patterns in bacterial prostatitis and urethritis, Invest Urol, 5, 492
- Hellstrom, 1987, Neuromuscular dysfunction in nonbacterial prostatitis, Urology, 30, 183, 10.1016/0090-4295(87)90193-2 · doi:10.1016/0090-4295(87)90193-2
- Barbalias, 1983, Prostatodynia: clinical and urodynamic characteristics, J Urol, 130, 514, 10.1016/S0022-5347(17)51281-1 · doi:10.1016/s0022-5347(17)51281-1
- Kirby, 1982, Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis, BJU Int, 54, 729, 10.1111/j.1464-410X.1982.tb13635.x · doi:10.1111/j.1464-410x.1982.tb13635.x
- Roehrborn, 2001, Alfuzosin: Overview of pharmacokinetics, safety, and efficacy of a clinically uroselective α-blocker, Urology, 58, 55, 10.1016/S0090-4295(01)01322-X · doi:10.1016/s0090-4295(01)01322-x
- Osborn, 1981, Prostatodynia—physiological characteristics and rational management with muscle relaxant, Br J Urol, 156, 621, 10.1111/j.1464-410X.1981.tb03275.x · DOI
- De La Rosette, 1992, Research in ‘prostatitis syndromes’: The use of alfuzosin (a new alfa 1 receptor blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities, Eur Urol, 22, 222, 10.1159/000474760 · doi:10.1159/000474760
- Cheah, 2003, Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: A randomized, placebo controlled trial, J Urol, 169, 592, 10.1016/S0022-5347(05)63960-2 · doi:10.1016/s0022-5347(05)63960-2
- Cheah, 2004, Initial, long term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome, Urology, 64, 881, 10.1016/j.urology.2004.06.041 · DOI · Paper page
- Evliyaoglu, 2002, Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with α-blocking agent doxazosin; versus placebo, Int Urol Nephrol, 34, 351, 10.1023/A:1024487604631 · DOI · Paper page
- Mehik, 2003, Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: A prospective, randomized, double-blind, placebo-controlled, pilot study, Urology, 62, 425, 10.1016/S0090-4295(03)00466-7 · DOI · Paper page
- Alexander, 2004, Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: A randomized, double blind trial, Ann Intern Med, 141, 581, 10.7326/0003-4819-141-8-200410190-00005 · DOI · Paper page
- Nickel, 2004, Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial, J Urol, 171, 1594, 10.1097/01.ju.0000117811.40279.19 · DOI
- Dinis, 2005, The distribution of sensory fibers immunoreactive for the TRPV1 (capsaicin) receptor in the human prostate, Eur Urol, 48, 162, 10.1016/j.eururo.2005.01.009 · DOI
- Canale, 1993, Use of a novel non-steroid anti-inflammatory drug, nimesulide, in the treatment of abacterial prostato-vesiculitis, Andrologia, 25, 163, 10.1111/j.1439-0272.1993.tb02701.x · doi:10.1111/j.1439-0272.1993.tb02701.x
- Nickel, 2001, Effects of rofecoxib in patients with chronic nonbacterial prostatitis: a placebo controlled pilot study, J Urol, 165, 27
- Shoskes, 2003, Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome, J Urol, 169, 1406, 10.1097/01.ju.0000055549.95490.3c · DOI
- Cornel, 2005, The effect of biofeedback physical therapy in men with chronic pelvic pain syndrome type III, Eur Urol, 47, 607, 10.1016/j.eururo.2004.12.014 · DOI · Paper page
Cited by
Rees, J., Abrahams, M., Doble, A., Cooper, A., & the Prostatitis Expert Reference Group (PERG) (2015) · BJU International · doi:10.1111/bju.13101 · Cited by 371
Metadata
- Authors
- Tuğcu, V., Taşçı, A. İ., Fazlıoğlu, A., Gürbüz, G., Özbek, E., Şahin, S., Kurtuluş, F., & Çek, M.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2007-04
- Volume
- 51
- Issue
- 4
- Pages
- 1113-1118
- ISSN
- 0302-2838
- Cited by
- 73
- References
- 0
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Placebo-Controlled Comparison of the Efficiency of Triple- and Monotherapy in Category III B Chronic Pelvic Pain Syndrome (CPPS). https://app.cochat.ai/papers/10.1016/j.eururo.2006.09.036
- The paper
- Tuğcu, V., Taşçı, A. İ., Fazlıoğlu, A., Gürbüz, G., Özbek, E., Şahin, S., Kurtuluş, F., & Çek, M. (2007). A Placebo-Controlled Comparison of the Efficiency of Triple- and Monotherapy in Category III B Chronic Pelvic Pain Syndrome (CPPS). European Urology. https://doi.org/10.1016/j.eururo.2006.09.036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.